Search

everythinglearnresearchcommunity

for

Search:↓

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

Antiphospholipid syndrome can severely damage adrenal glands, requiring early diagnosis and treatment.

Some patients developed hair loss after islet cell transplant possibly due to their immune-suppressing medications.

Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.

Atypical symptoms in lupus can indicate different kidney issues.

Dystonia may be part of PAS-4 and linked to immune issues.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

ILC1 cells contribute to hair loss in alopecia areata.

Men with male pattern baldness may be more at risk for severe COVID-19, and anti-androgen treatments could offer protection.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Immunological skin diseases in pigs are rare and can be caused by immune system issues or external factors.

AHST shows promise for treating type 1 diabetes but needs more research before widespread use.

Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Nonimmunogenic forms of keratins K71 and K31 can delay and prevent alopecia areata.

Monoclonal antibodies are often linked to alopecia areata cases.

Allergens might contribute to CCCA, so avoiding them could help manage the condition.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

Alopecia areata patients have higher levels of IL-6 and TNF-α.

Higher Alarin levels may predict androgenetic alopecia and metabolic syndrome.

Newer GLP-1 drugs like semaglutide may cause hair loss.

IVIG therapy was linked to hair regrowth in two patients with hair loss, but it's not recommended due to its risks and costs.

Inflammation and immunity play a key role in androgenetic alopecia, with better treatment outcomes in certain immune-positive cases.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

The study concluded that there is no significant link between thyroid autoimmunity and alopecia areata.